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Overnight
(reference) Ambulatory
Hazard Ratio (95%
CI)
p
value
no./total no.
(%)
no./total no.
(%)
Low ACEF
MACE 7/618 (1.1) 18/2214 (0.8) 0.716 (0.299 – 1.714) 0.453
Readmission 4/618 (0.6) 16/2214 (0.7)
All-cause
Death
1/618 (0.2) 0/2214 (0)
MI 4/618 (0.6) 3/2214 (0.1)
High ACEF
MACE 35/1098 (3.2) 22/1002 (2.2) 0.683 (0.401 – 1.165) 0.162
Readmission 14/1098 (1.3) 18/1002 (1.8)
All-cause
Death
20/1098 (1.8) 4/1002 (0.4)
MI 4/1098 (0.4) 1/1002 (0.1)
ACEF score: age/left ventricular ejection fraction 	 1 (if creatinine 2 mg/dl).
Conclusions: In this single-center registry, patients who underwent ambulatory PCI had
no worse outcomes than those who stayed at least one night, at high and low ACEF
scores.
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Background: The aim of this study was to evaluate the frequency, predictors and the
clinical outcome of stent thrombosis after DES implantation and bare metal stent (BMS)
implantation in Asian races.
Methods: A total of 14,577 consecutive patients who underwent successful DES
implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38% of
the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients) were
included in this study. We evaluate the frequency, predictor of stent thrombosis.
Results: At a mean follow-up of 78.529.9 months in DES and 81.826.4 months in
BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis
(SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18% with
DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year with DES
and no BMS. Independent predictors of stent thrombosis are bifurcation lesion (OR1.90,
95% CI: 1.83 to 24.24, p0.01) and ejection fraction (OR0.90, 95% CI: 0.86 to 0.94,
p0.03). Only 0.2 % of the patients were died because of the myocardial infarction after
stent thrombosis in both groups.
Conclusions: The incidence of stent thrombosis in Asian races is relatively low (0.5 %
with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent
thrombosis) at mean follow-up to 7 years. Particular attention will need to be directed to
this complication when the patients have bifurcation lesions or low ejection fraction.
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Background: Aims: To evaluate safety and effectiveness of the Elixir DESyneTM
Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor
Zotarolimus-Eluting CSS through assessment of clinical, angiographic, and IVUS
endpoints.
Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with 5mcg
per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable
methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of stent length
of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were
analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9 months.
All patients also underwent evaluation for secondary endpoints which included a
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent
thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents
were also assessed for angiographic endpoints at 9 months including: in-stent and
in-segment LLL. A subset of patients underwent IVUS evaluation including percent
neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also
demonstrated superiority of the DESyne CSS as compared to control.
Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results
through 2 years which trend lower for the DESyne stent.
Table 1: 9-month Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
Baseline RVD (post-
procedure)
2.84 0.43 2.91 0.38 0.2
9-month angiographic/IVUS
In-stent LLL 0.11 0.32 0.63 0.42  0.001
% neointimal volume 4.5 5.1 20.9 11.3 0.001
Clinical Results
12-month DoCE (%) 4.3 7.0 0.51
Clinically-indicated TLR 1.4 5.6 0.18
24-month DoCE (%) 4.3 9.0 0.14
Clinically-indicated TLR 1.4 7.0 0.045
Conclusions: The study met the non-inferiority endpoint and also demonstrated
superiority of the DESyne CSS as compared to control. Clinical results through 3 years
and a review of angiographic and IVUS results will be presented.
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Background: Drug eluting stents (DES) have been shown to significantly decrease
restenosis with subsequent need for lesion and/or vessel revascularization when compared
with bare metal stents (BMS) in selected patient groups in both randomized controlled
trials and in observational registries. If their use in all-comers is also associated with a
survival benefit over a longer follow-up is controversial.
Methods: Retrospective analysis of the MIDAS registry for patients who underwent PCI
with BMS between January 1 1997-December 31 1998 (pre DES era, group 1; N
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